Capricor Therapeutics Inc (CAPR)

Jan 31, 2025

How to Take Advantage of moves in (CAPR) - Stock Traders Daily

Jan 31, 2025

Jan 29, 2025

Capricor wins key EU designations for the lead asset - MSN

Jan 29, 2025

Jan 26, 2025

JPMorgan Chase & Co. Purchases 45,381 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World

Jan 26, 2025

Jan 26, 2025

JPMorgan Chase & Co. Raises Stock Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat

Jan 26, 2025

Jan 23, 2025

Magnus Financial Group LLC Invests $276,000 in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat

Jan 23, 2025

Jan 23, 2025

Equities Analysts Set Expectations for CAPR FY2025 Earnings - Defense World

Jan 23, 2025

Jan 23, 2025

Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50 - Defense World

Jan 23, 2025

Jan 22, 2025

Analysts Set Expectations for CAPR FY2025 Earnings - MarketBeat

Jan 22, 2025

Jan 22, 2025

Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone - Yahoo Finance

Jan 22, 2025

Jan 21, 2025

When the Price of (CAPR) Talks, People Listen - Stock Traders Daily

Jan 21, 2025

Jan 21, 2025

Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 53% CAGR over 5 years, surging 8.8% in the last week alone - Simply Wall St

Jan 21, 2025

Jan 20, 2025

Krilogy Financial LLC Makes New $287,000 Investment in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat

Jan 20, 2025

Jan 20, 2025

Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Jan 20, 2025

Jan 18, 2025

Barclays PLC Has $552,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World

Jan 18, 2025

Jan 18, 2025

Barclays PLC Buys 18,724 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat

Jan 18, 2025

Jan 17, 2025

Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade - MSN

Jan 17, 2025

Jan 16, 2025

Will Capricor's Deramiocel Make History As The First Approved Treatment For DMD Cardiomyopathy? - RTTNews

Jan 16, 2025

Jan 15, 2025

Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Growth in Short Interest - MarketBeat

Jan 15, 2025

Jan 15, 2025

Dilated Cardiomyopathy Pipeline Overview 2024: FDA Approvals and Key Developments | Vericel Corporation, AstraZeneca, Pfizer, Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics - The Globe and Mail

Jan 15, 2025

Jan 15, 2025

Certain Common Stock of Capricor Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2025. - Marketscreener.com

Jan 15, 2025

Jan 15, 2025

Capricor's CAP-1002: A New Hope For Duchenne Muscular Dystrophy? - RTTNews

Jan 15, 2025

Jan 07, 2025

Application finalized for DMD cell therapy CAP-1002, now deramiocel - Muscular Dystrophy News

Jan 07, 2025

Jan 05, 2025

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA - MSN

Jan 05, 2025

Jan 04, 2025

Capricor Therapeutics Completes BLA Submission for Deramiocel Treatment of Duchenne Muscular Dystrophy - Defense World

Jan 04, 2025

Jan 03, 2025

CAPR Stock Up On Completion Of Rolling Submission Of DMD Drug BLA - Barchart

Jan 03, 2025

Jan 03, 2025

Capricor Therapeutics (NASDAQ:CAPR) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat

Jan 03, 2025

Jan 03, 2025

Capricor stock reiterated at Buy at H.C. Wainwright By Investing.com - Investing.com Canada

Jan 03, 2025

Jan 03, 2025

Capricor Therapeutics Stock Surges On BLA Submission for Cell Therapy To Treat Muscular Dystrophy: Retail’s Excited - MSN

Jan 03, 2025

Jan 03, 2025

Capricor files cell therapy for DMD cardiomyopathy with FDA - pharmaphorum

Jan 03, 2025

Jan 02, 2025

Capricor completes U.S. marketing submission for lead candidate - MSN

Jan 02, 2025

Jan 02, 2025

Capricor completes BLA submission for deramiocel - The Pharma Letter

Jan 02, 2025

Jan 02, 2025

Beyond The Numbers: 7 Analysts Discuss Capricor Therapeutics Stock - Benzinga

Jan 02, 2025

Jan 02, 2025

HC Wainwright Reaffirms "Buy" Rating for Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat

Jan 02, 2025

Jan 02, 2025

Capricor seeks U.S. marketing nod for DMD drug (CAPR:NASDAQ) - Seeking Alpha

Jan 02, 2025

Jan 02, 2025

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy - The Manila Times

Jan 02, 2025

Jan 02, 2025

Capricor completes FDA submission for DMD therapy By Investing.com - Investing.com Canada

Jan 02, 2025

Jan 02, 2025

Capricor Therapeutics Completes Submission of Biologics - GlobeNewswire

Jan 02, 2025

Dec 31, 2024

(CAPR) Trading Report - Stock Traders Daily

Dec 31, 2024

Dec 31, 2024

Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Increase in Short Interest - Defense World

Dec 31, 2024

Dec 29, 2024

Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 26.8% in December - MarketBeat

Dec 29, 2024

Dec 29, 2024

Analysts Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $34.50 - Defense World

Dec 29, 2024

Dec 28, 2024

State Street Corp Has $7.79 Million Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat

Dec 28, 2024

Dec 26, 2024

Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) PT at $34.50 - MarketBeat

Dec 26, 2024

Dec 24, 2024

Capricor Therapeutics (NASDAQ:CAPR) Trading Down 2.9%What's Next? - MarketBeat

Dec 24, 2024

Dec 24, 2024

Capricor Therapeutics (CAPR) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com

Dec 24, 2024

Dec 23, 2024

Capricor Therapeutics (NASDAQ:CAPR) Trading 5.6% HigherWhat's Next? - MarketBeat

Dec 23, 2024

Dec 20, 2024

(CAPR) Trading Advice - Stock Traders Daily

Dec 20, 2024

Dec 18, 2024

Capricor Therapeutics (CAPR) Stock Dips Amid Biotech Sector Decl - GuruFocus.com

Dec 18, 2024